What Mass Spectrometry Can and Cannot Confirm About a Peptide

What does a matching mass actually establish?

It establishes that something in the sample has the expected mass, which is meaningful evidence and is not the same as proof of the sequence. Mass is a summary property. Rearrangements of the same residues share it, and a modification that adds and removes equal mass leaves it unchanged. Treating a single intact-mass match as a complete identity result asks one measurement to answer a question it does not fully address.

The characterisation practice for reference materials reflects this. McCarthy and colleagues note that multiple methods are used to confirm the identity of peptide sequences, listing NMR, mass spectrometry, chromatographic retention time and chiral analysis. Chiral analysis is a useful illustration of the gap: a D-amino acid substituted for an L-amino acid changes neither the mass nor the formula, so no mass measurement can detect it, and a separate method is required.

Sources: McCarthy et al., Pharmaceutical Research (2023): Reference standards to support quality of synthetic peptides

What does tandem MS add over an intact mass?

Fragmentation turns a single summary number into a set of observations that depend on the order of the residues, which is what makes sequence evidence possible at all. The NIST report for reference material RM 8321 describes characterising synthetic peptides by LC–MS and LC–MS/MS, assessing identity, purity, and both chromatographic and mass spectrometric behaviour, then using further LC–MS/MS analyses and spectral comparisons to assess the mixture as a whole.

Two limits are worth carrying into any document review. Fragment coverage is rarely complete, so a region of the sequence may be supported by no fragment at all. And components that ionise poorly can be under-represented relative to how much of them is present, which is a reason mass spectrometric response is not a quantity measurement. Ask what evidence was actually collected for your material rather than inferring it from the technique.

Sources: NIST RM 8321: Peptide Mixture for Proteomics — historical report of investigation

Why is identity separated from purity and content?

ICH Q2(R2) treats identity, purity or impurities, and assay or content as distinct analytical purposes, and ties validation to the intended use of the procedure. The separation is not bureaucratic. A method optimised to confirm that the right compound is present may be poor at quantifying how much is there, and a method that quantifies well may not distinguish the target from a close structural relative.

In practice this means an identity result cannot be read as a purity claim, and a purity percentage cannot be read as confirmation of the sequence. When a certificate reports one and not the other, the missing one is genuinely missing rather than implied. Keep the fields separate in your own records and note the method beside each, so that the absence of a result stays visible instead of being smoothed over later.

Sources: ICH Q2(R2): Validation of Analytical Procedures (2023)

What should you ask about identity evidence?

Ask which identity methods were run, not merely which instruments exist. Ask whether fragmentation data were collected and what sequence coverage they provided. Ask whether stereochemistry was assessed, since no mass measurement addresses it. Where a spectrum is referenced, ask whether the underlying data can be reviewed rather than only the summary conclusion drawn from it.

Record the answers, including the cases where the answer is that a test was not performed. A missing identity method is an open question, not a passing result, and it is easier to hold that distinction at the point of purchase than to reconstruct it afterwards. For Savage Labs records, send support the compound name, vial size, batch identifier if known, and order number if applicable. These resources support document literacy for in vitro laboratory research and do not establish suitability for human or veterinary use.